GlassScriptPhysician profile
Drew Munson Anderson
NPI 1609832377
$14,412.99
in general payments reported to CMS, 2019-2025
30 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,547 · 2020: $1,584 · 2021: $1,692 · 2022: $1,849 · 2023: $2,170 · 2024: $1,918 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,466 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,466.02 |
| Education | $275.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,718.89 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $2,539.65 | 2019-2025 | |
| Janssen Biotech, INC. | $1,301.64 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,173.86 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $957.85 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $946.85 | 2019-2025 | |
| Ucb, INC. | $618.89 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $551.17 | 2021-2025 | Opzelura |
| Amgen INC. | $482.49 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $443.97 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $421.92 | 2020-2025 | Adbry, Anzupgo |
| Pfizer INC. | $417.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $329.22 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $301.80 | 2019-2023 | Jublia |
| Galderma Laboratories, L.P. | $216.32 | 2021-2025 | Nemluvio, Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.54 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $151.05 | 2019-2021 | |
| Celgene Corporation | $137.17 | 2019 | |
| Janssen Scientific Affairs, LLC | $123.76 | 2019 | |
| Mallinckrodt Hospital Products INC. | $119.25 | 2022-2025 | Acthar |
| Genentech USA, INC. | $70.14 | 2019-2021 | |
| Dermavant Sciences, INC. | $60.42 | 2022-2024 | Vtama |
| Organogenesis INC. | $27.41 | 2023 | Puraply |
| Medtronic, INC. | $24.98 | 2021 | |
| Hologic Sales and Service, LLC | $24.16 | 2024 | Myosure Tissue Removal Device, Fluent Fluid Management System |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Allergan, INC. | $20.15 | 2020 | |
| Aclaris Therapeutics, INC. | $13.70 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.58 | 2019 | |
| Biofrontera INC. | $9.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.